开云app官网登录入口网页版-官方正版

#里程碑#

100篇内容 | 2252人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2059343, encodeId=21912059343ad, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=ASCO2022 | 里程碑式突破！DESTINYBreast04结果显示，T-DXd对HER2-低表达mBC安全有效！, objectType=article, longId=728766, objectId=ebf0e2876637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebf0e2876637, replyNumber=0, likeNumber=87, createdTime=2023-02-10, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebf0e2876637, moduleTitle=ASCO2022 | 里程碑式突破！DESTINYBreast04结果显示，T-DXd对HER2-低表达mBC安全有效！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ebf0e2876637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059344, encodeId=973320593444d, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展, objectType=article, longId=732978, objectId=3ce1e32978e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ce1e32978e9, replyNumber=0, likeNumber=92, createdTime=2022-08-02, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ce1e32978e9, moduleTitle=百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=3ce1e32978e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059340, encodeId=7718205934018, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批, objectType=article, longId=725721, objectId=8aebe257213e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aebe257213e, replyNumber=0, likeNumber=0, createdTime=2022-07-06, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aebe257213e, moduleTitle=重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8aebe257213e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059338, encodeId=d0072059338a4, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=Lancet Neuro：里程碑进展！世界首次朊病毒病的人体治疗实验，结果令人鼓舞, objectType=article, longId=301167, objectId=ae6930116e90, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6930116e90, replyNumber=0, likeNumber=84, createdTime=2023-02-17, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6930116e90, moduleTitle=Lancet Neuro：里程碑进展！世界首次朊病毒病的人体治疗实验，结果令人鼓舞, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ae6930116e90)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059345, encodeId=503d2059345d9, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=罕见病药物「依库珠单抗」在华收获里程碑进展，为罕见病治疗提供新选择, objectType=article, longId=737466, objectId=2b60e37466f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b60e37466f8, replyNumber=0, likeNumber=96, createdTime=2022-12-07, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b60e37466f8, moduleTitle=罕见病药物「依库珠单抗」在华收获里程碑进展，为罕见病治疗提供新选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2b60e37466f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059339, encodeId=d62920593398b, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=再迎出海里程碑，百泽安®肺癌和食管癌上市许可申请获欧洲药品管理局受理, objectType=article, longId=301671, objectId=94873016e162, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94873016e162, replyNumber=0, likeNumber=86, createdTime=2022-09-03, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94873016e162, moduleTitle=再迎出海里程碑，百泽安®肺癌和食管癌上市许可申请获欧洲药品管理局受理, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=94873016e162)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059337, encodeId=66a0205933e1f, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=Aerogen®和康希诺生物就吸入给药新冠疫苗的开发和商业供货建立里程碑式的合作伙伴关系, objectType=article, longId=291853, objectId=fdf129185389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdf129185389, replyNumber=0, likeNumber=106, createdTime=2022-11-17, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdf129185389, moduleTitle=Aerogen®和康希诺生物就吸入给药新冠疫苗的开发和商业供货建立里程碑式的合作伙伴关系, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=fdf129185389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059341, encodeId=f1a32059341ee, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=新里程碑临床研究：后生元尿石素A (Mitopure™)可提高中年人肌肉力量和运动体能, objectType=article, longId=727373, objectId=54b0e2737391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b0e2737391, replyNumber=0, likeNumber=90, createdTime=2022-12-01, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b0e2737391, moduleTitle=新里程碑临床研究：后生元尿石素A (Mitopure™)可提高中年人肌肉力量和运动体能, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=54b0e2737391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059342, encodeId=0263205934278, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=疫苗学进展的里程碑事件，一段波澜壮阔的历史！值得收藏, objectType=article, longId=727757, objectId=ddcce27757b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddcce27757b4, replyNumber=0, likeNumber=0, createdTime=2023-03-10, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddcce27757b4, moduleTitle=疫苗学进展的里程碑事件，一段波澜壮阔的历史！值得收藏, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ddcce27757b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059336, encodeId=d563205933652, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=JACC：肿瘤治疗里程碑——注意万能CAR-T疗法的心肺不良事件！, objectType=article, longId=219460, objectId=63ca21946033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ca21946033, replyNumber=0, likeNumber=68, createdTime=2022-03-07, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ca21946033, moduleTitle=JACC：肿瘤治疗里程碑——注意万能CAR-T疗法的心肺不良事件！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=63ca21946033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059334, encodeId=a75920593342e, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=NEJM：我国学者里程碑式研究，老年高血压患者强化降压确实更佳！, objectType=article, longId=216600, objectId=6f8321660051, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f8321660051, replyNumber=0, likeNumber=77, createdTime=2021-11-06, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f8321660051, moduleTitle=NEJM：我国学者里程碑式研究，老年高血压患者强化降压确实更佳！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6f8321660051)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059333, encodeId=f173205933357, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=里程碑 | 牛津学者：糖尿病患者早期控糖决定未来20年的死亡风险！, objectType=article, longId=214221, objectId=768d21422132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=768d21422132, replyNumber=0, likeNumber=84, createdTime=2022-05-08, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=768d21422132, moduleTitle=里程碑 | 牛津学者：糖尿病患者早期控糖决定未来20年的死亡风险！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=768d21422132)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059332, encodeId=d86520593324b, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗, objectType=article, longId=212620, objectId=76ec212620dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ec212620dd, replyNumber=0, likeNumber=63, createdTime=2021-07-19, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ec212620dd, moduleTitle=里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=76ec212620dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059328, encodeId=0f88205932803, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=里程碑！全国97家医院联合发文：中药麝香保心丸联合阿司匹林使用，可使冠心病患者的心血管不良事件发生率降低26.9%, objectType=article, longId=210232, objectId=a54b210232fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54b210232fc, replyNumber=0, likeNumber=95, createdTime=2021-07-01, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54b210232fc, moduleTitle=里程碑！全国97家医院联合发文：中药麝香保心丸联合阿司匹林使用，可使冠心病患者的心血管不良事件发生率降低26.9%, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a54b210232fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059335, encodeId=8c1d20593358b, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=辉凌将在IDWeek 2021上呈报基于微生物组的在研活体生物治疗药物RBX2660的获奖里程碑式研究, objectType=article, longId=217802, objectId=61bb21e8022f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61bb21e8022f, replyNumber=0, likeNumber=68, createdTime=2022-08-08, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61bb21e8022f, moduleTitle=辉凌将在IDWeek 2021上呈报基于微生物组的在研活体生物治疗药物RBX2660的获奖里程碑式研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=61bb21e8022f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059325, encodeId=d18f205932575, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=化疗药物剂量如何把握？新的里程碑研究为有效监测癌症患者的化疗药物水平带来希望, objectType=article, longId=209580, objectId=07d02095806b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07d02095806b, replyNumber=0, likeNumber=98, createdTime=2021-08-11, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07d02095806b, moduleTitle=化疗药物剂量如何把握？新的里程碑研究为有效监测癌症患者的化疗药物水平带来希望, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=07d02095806b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059322, encodeId=e0fa2059322e6, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=EORTC赞助的MINDACT研究试验在《柳叶刀·肿瘤学分册》上发表具有里程碑意义的长期数据, objectType=article, longId=208473, objectId=22c12084e366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22c12084e366, replyNumber=0, likeNumber=93, createdTime=2021-06-28, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22c12084e366, moduleTitle=EORTC赞助的MINDACT研究试验在《柳叶刀·肿瘤学分册》上发表具有里程碑意义的长期数据, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=22c12084e366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059330, encodeId=972e205933055, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=NEJM里程碑式定论：高血压患者收缩压＜120mmHg可显著降低心血管死亡率！, objectType=article, longId=211679, objectId=df242116e94c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df242116e94c, replyNumber=0, likeNumber=73, createdTime=2021-06-29, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df242116e94c, moduleTitle=NEJM里程碑式定论：高血压患者收缩压＜120mmHg可显著降低心血管死亡率！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=df242116e94c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059329, encodeId=91332059329de, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=Novavax新冠疫苗寄予厚望，后起之秀疟疾疫苗迎来里程碑, objectType=article, longId=210580, objectId=cae52105802a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cae52105802a, replyNumber=0, likeNumber=69, createdTime=2021-07-29, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cae52105802a, moduleTitle=Novavax新冠疫苗寄予厚望，后起之秀疟疾疫苗迎来里程碑, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cae52105802a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059331, encodeId=a030205933154, content=<a href='/topic/show?id=9fbe95e0015' target=_blank style='color:#2F92EE;'>#里程碑#</a>, objectTitle=无创新疗法治疗震颤取得里程碑进展，“磁波刀”神外解决方案获批药监局批准在华正式投入临床, objectType=article, longId=211775, objectId=e164211e7541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e164211e7541, replyNumber=0, likeNumber=111, createdTime=2022-01-21, rootId=0, userName=xzw113, userId=2317301, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e164211e7541, moduleTitle=无创新疗法治疗震颤取得里程碑进展，“磁波刀”神外解决方案获批药监局批准在华正式投入临床, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=e164211e7541)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

里程碑

2020-05-29

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

ASCO2022 | 里程碑式突破！DESTINYBreast04结果显示，T-DXd对HER2-低表达mBC安全有效！

2023-02-10

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

百奥赛图与LiberoThera共同开发全人GPCR抗体药物取得里程碑式进展

2022-08-02

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

重磅里程碑：肺癌创新药第三代ALK抑制剂洛拉替尼在中国获批

2022-07-06

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

Lancet Neuro：里程碑进展！世界首次朊病毒病的人体治疗实验，结果令人鼓舞

2023-02-17

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

罕见病药物「依库珠单抗」在华收获里程碑进展，为罕见病治疗提供新选择

2022-12-07

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

再迎出海里程碑，百泽安®肺癌和食管癌上市许可申请获欧洲药品管理局受理

2022-09-03

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

Aerogen®和康希诺生物就吸入给药新冠疫苗的开发和商业供货建立里程碑式的合作伙伴关系

2022-11-17

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

新里程碑临床研究：后生元尿石素A (Mitopure™)可提高中年人肌肉力量和运动体能

2022-12-01

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

疫苗学进展的里程碑事件，一段波澜壮阔的历史！值得收藏

2023-03-10

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

JACC：肿瘤治疗里程碑——注意万能CAR-T疗法的心肺不良事件！

2022-03-07

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

NEJM：我国学者里程碑式研究，老年高血压患者强化降压确实更佳！

2021-11-06

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

里程碑 | 牛津学者：糖尿病患者早期控糖决定未来20年的死亡风险！

2022-05-08

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

里程碑！免疫“双子星”获国家药品监督管理局批准用于恶性胸膜间皮瘤一线治疗

2021-07-19

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

里程碑！全国97家医院联合发文：中药麝香保心丸联合阿司匹林使用，可使冠心病患者的心血管不良事件发生率降低26.9%

2021-07-01

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

辉凌将在IDWeek 2021上呈报基于微生物组的在研活体生物治疗药物RBX2660的获奖里程碑式研究

2022-08-08

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

化疗药物剂量如何把握？新的里程碑研究为有效监测癌症患者的化疗药物水平带来希望

2021-08-11

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

EORTC赞助的MINDACT研究试验在《柳叶刀·肿瘤学分册》上发表具有里程碑意义的长期数据

2021-06-28

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

NEJM里程碑式定论：高血压患者收缩压＜120mmHg可显著降低心血管死亡率！

2021-06-29

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

Novavax新冠疫苗寄予厚望，后起之秀疟疾疫苗迎来里程碑

2021-07-29

xzw113 (审核中...)

前往app查看评论内容

#里程碑#

无创新疗法治疗震颤取得里程碑进展，“磁波刀”神外解决方案获批药监局批准在华正式投入临床

2022-01-21

科室
- - 订阅+
  - 更多科室
工具
服务